Nov 10, 2026  ·  1 min read

SRTD Biotech raises €31.5 million for RNA medicines targeting diseased cells

Getting a medicine into the right organ does not guarantee it will act only on diseased cells. SRTD Biotech, a drug-development startup in Jülich, Germany, has raised €31.5 million to pursue more selective RNA medicines. RNA is a molecule that can carry instructions for making proteins. The company says its designs recognize signs of disease inside cells and activate those instructions there, aiming to limit exposure in healthy tissue.

The funding will support preclinical development: laboratory and other work before human trials. SRTD is pursuing potential treatments for cancer, diseases in which the immune system attacks the body, and conditions involving tissue scarring. The approach remains experimental. Its promise depends on a precise distinction: recognizing disease from signals inside a cell, then activating the treatment there.

Source  ·  merieux-partners.com ↗

  1. Nov 17Helus says its psychedelic pill beat placebo in a depression trial
  2. Nov 17Anthropic adds text watermarking to four Claude 4 models
  3. Nov 17HHS finalizes HIPAA changes: 15-day record access and health app transfers
  4. Nov 17FBI warns attackers are using the Artex AI hacking tool against companies
  5. Nov 16OpenAI lets its AI helpers complete your purchases

This is our sketchbook.

Two stoneware cups turned towards each other, as if in conversation

Got a good project?
Let’s work on it together.

Let’s talk →

info@ndot.io · New Jersey · Budapest · Biel